4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary
California-based biotech 4D Molecular Therapeutics (4DMT) will be acquiring the rights to an asset from a company under the Fortress Biotech umbrella.
On Monday, 4DMT announced it has secured rights to the short-form human complement factor H (sCFH) asset from Aevitas Therapeutics, a subsidiary of Fortress Biotech. The asset, invented at the University of Pennsylvania, is a form of a natural inhibitor of the inflammatory complement pathway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.